Advertisement
Advertisement

KALV

KALV logo

KalVista Pharmaceuticals Inc

8.88
USD
+0.23
+2.66%
Dec 18, 14:03 UTC -5
Open

KalVista Pharmaceuticals Inc Profile

About

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States.

Info & Links

CEO

Benjamin L. Palleiko

Headquarters

55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE, MA 02142, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

https://www.kalvista.com

Auditor

Deloitte & Touche LLP

Share holders

20

Employees

150

KalVista Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

383.79M

Enterprise Value

351.95M

Enterprise Value/EBITDA(ttm)

-2.28

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

3.20

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-103.92%

Return on Invested Capital(ttm)

-101.95%

Return on Assets(ttm)

-88.06%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-154.68M

Net Income Available to Common(ttm)

-141.77M

Diluted EPS(ttm)

-3.64

Share Statistics

Beta (5Y Monthly)

0.85

52-Week Change

-0.11%

S&P 500 52-Week Change

27.86%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

43.22M

Dividend Yield

0.00%

Float4

44.23M

% Held by Insiders

10.50%

% Held by Institutions

0.00%

Balance Sheet

Total Cash(mrq)

174.27M

Total Cash Per Share(mrq)

4.03

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

8.55%

Quick Ratio(mrq)

6.87%

Book Value Per Share(mrq)

4.01

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.87

Free Cash Flow(ytd)

-40.30M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement